Case Report|Articles in Press

Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing

Published:February 08, 2023DOI:

      Clinical Practice Points

      • Plasma-based next-generation sequencing can potentially identify additional driver alterations in patients with NSCLC compared to single-gene testing for EGFR, ALK and ROS1; this can be relevant when there is limited tissue for molecular profiling or if tissue biopsy is not feasible.
      • The identification of driver alterations in plasma helps NSCLC patients to be treated with matched targeted therapy, which eventually might lead to better outcomes.
      • Further studies exploring the cost-effectiveness of complementary liquid biopsy in addition to tissue genotyping are warranted, as well as novel strategies such as a tissue-sparing, plasma-first approach.
      • Timely and equitable access to targeted therapies will also be critical to translate research in precision medicine into improved patient care.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hendriks LE
        • Kerr K
        • Menis J
        • et al.
        Oncogene-addicted metastatic non–small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
        Ann Oncol. 2023;
        • Nadler E
        • Vasudevan A
        • Wang Y
        • Ogale S
        Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non–small-cell lung cancer patients in the US oncology network.
        Cancer Treat Res Commun. 2022; 31100522
        • Robert NJ
        • Espirito JL
        • Chen L
        • et al.
        Biomarker testing and tissue journey among patients with metastatic non–small-cell lung cancer receiving first-line therapy in The US Oncology Network.
        Lung Cancer. 2022; 166: 197-204
        • Provencio M
        • Cobo M
        • Rodriguez-Abreu D
        • et al.
        Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
        BMC Cancer. 2022; 22: 732
        • Griesinger F
        • Eberhardt W
        • Nusch A
        • et al.
        Biomarker testing in non–small-cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315).
        Lung Cancer. 2021; 152: 174-184
        • Gordan LN
        • Diaz M
        • Patel AJ
        • et al.
        Effective biomarker testing rates in a large U.S. community practice.
        JCO. 2022; 40: e21093
        • Rolfo C
        • Mack P
        • Scagliotti GV
        • et al.
        Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer.
        J Thorac Oncol. 2021; 16: 1647-1662
        • Leighl NB
        • Page RD
        • Raymond VM
        • et al.
        Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small-cell lung cancer.
        Clin Cancer Res. 2019; 25: 4691-4700
        • Pennell NA
        • Mutebi A
        • Zhou ZY
        • et al.
        Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model.
        JCO Precis Oncol. 2019; 3: 1-9
        • Mosele F
        • Remon J
        • Mateo J
        • et al.
        Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
        Ann Oncol. 2020; 31: 1491-1505
        • Lindeman NI
        • Cagle PT
        • Aisner DL
        • et al.
        Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
        Arch Pathol Lab Med. 2018; 142: 321-346
        • Paz-Ares L
        • Gondos A
        • Saldana D
        • et al.
        Genomic testing among patients with newly diagnosed advanced non–small-cell lung cancer in the United States: a contemporary clinical practice patterns study.
        Lung Cancer. 2022; 167: 41-48
        • Kalemkerian GP
        • Narula N
        • Kennedy EB
        • et al.
        Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
        JCO. 2018; 36: 911-919
        • Zugazagoitia J
        • Ramos I
        • Trigo JM
        • et al.
        Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
        Ann Oncol. 2019; 30: 290-296
        • Aggarwal C
        • Marmarelis ME
        • Hwang WT
        • et al.
        Association of comprehensive molecular genotyping and overall survival in patients with advanced nonsquamous non–small-cell lung cancer.
        JCO. 2022; 40: 9022